.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Ophthalmology

Biosimilar Competition for Ranibizumab Lies Ahead as Developers Undertake Phase 3 Trials

August 26th 2017

By Kelly Davio

Article

Roche’s sales of ranibizumab (Lucentis), already depleted by competition from such products as afilbercept (Eylea), face upcoming erosion from biosimilar competition.

Advances in the Development of Ranibizumab and Teriparatide Biosimilars

April 25th 2017

By Jackie Syrop

Article